BIOVAIL EXTENDS MARKETING PACT FOR ZOVIRAX OINTMENT/CREAM.Biovail Corporation (NYSE NYSE See: New York Stock Exchange :BVF BVF Biovail Corporation (stock symbol) BVF Berufsverband der Frauenärzte eV (Muenchen, Germany) BVF Bearing Versus Frequency )(TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension :BVF), Toronto, has extended its agreement with GlaxoSmithKline plc (GSK) for the marketing rights to Zovirax(R) Ointment and Zovirax Cream to 20 years from ten years for a payment of $40 million. Zovirax Ointment is used topically for the treatment of herpes genitalis (genital herpes) and Zovirax(R) Cream is used topically in the treatment of recurrent herpes labialis (cold sores) in adults and adolescents (12 years of age and older). "We are pleased with the opportunity to extend the duration of our promotion agreement for this market-leading brand," commented Eugene Melnyk, chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Biovail. "We anticipate receiving U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) approval for Zovirax(R) Cream with an anticipated launch in the second quarter of 2003." Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, sale and promotion of pharmaceutical products utilizing advanced drug delivery technologies. For further information, call 905-286-3000 or visit http://www.biovail.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion